Thermostable Biopharmaceuticals For Delivery Without Reconstitution
|
|
- Matilda Stephens
- 5 years ago
- Views:
Transcription
1 Thermostable Biopharmaceuticals For Delivery Without Reconstitution V. Bronshtein Supported by NIH Grants U01AI070350, 5R44AI080035, 5R21AI094508, and CDC Contract Number
2 Bottlenecks for Effective Applications of Vaccines and Other Fragile Biopharmaceuticals A need for maintaining a cold chain for vaccine storage and distribution. A need for reconstitution of vaccines with sterile water or aqueous solutions. A need for a conventional needle-based parental vaccine delivery. A need for using trained medical personal and special facilities for parental vaccination.
3 Could Biopharmaceuticals Be Delivered Without Reconstitution Using Methods Developed for Conventional Pharmaceuticals? Many conventional pharmaceuticals could be stored at ambient temperatures (AT) and delivered via oral (intestinal, sublingual, and buccal), transdermal, respiratory, vaginal, and anal delivery routes without reconstitution with water before the delivery, avoiding painful parenteral delivery and help of medical personal. Pharmaceutical industry had developed sophisticated methods and tools for production, tablets, dissolvable films, patches, suppositories, ointment, creams, and capsules (including enteric coated capsules for intestinal delivery) that are used for needle free delivery of the pharmaceuticals. The question is what is stopping us from doing the same for biopharmaceuticals?
4 Industry Problem: Most of Bio-pharmaceuticals (i.e. vaccines) currently produced using freeze-drying (FD) or spray-drying (SD) are not thermostable. Still, despite major limitations and shortcomings, freeze-drying and spraydrying remain the primary methods for stabilization of vaccines and other biopharmaceuticals in the dry state. Procedures that are currently used for preparation tablets, dissolvable films, patches, suppositories, ointment, etc. often include usage of materials and substances that are harmful for dry preserved biopharmaceuticals. In addition, they may include short term application of high temperatures, shear stresses, and other harmful conditions, destroying biologicals.
5 UST Solution for Production of Micronized Thermostable Biopharmaceuticals: First: Thermostabilization using PBV technology. Second: Micronization of the thermostable product using jet milling.
6 History and Development of Foam Drying and Preservation by Vaporization (PBV) Annear preserved bacteria by foaming a syrup under vacuum. The syrup was obtained by evaporation. No freezing of the material was involved. Drawbacks: The process is applicable only to small volumes (several ml or less) of material. Syrup often does not foam Roser and Gibbon proposed to use the same (Annear) process for other biologics Bronshtein proposed using Preservation by Foam Formation (PFF) as an alternative to freeze-drying (Pharmaceutical Technology 28, 86-92, 2004). He suggested obtaining the syrup by boiling in order to make the process scalable. Drawbacks: Splashing, difficult to control and reproduce PFF process Bronshtein proposed Preservation by Vaporization (PBV), during which a partially frozen material sublimates, boils and evaporates simultaneously (PCT Patent Application WO A). It is scalable, easy to control and reproduce, and has minimum splashing...
7 Outside Research Supports the Superior Thermostability Offered by Foam Drying Monoclonal antibodies: Abdul-Fattah AM et al J Pharm Sci. 96 (8): Parainfluenza strain vaccine: Abdul-Fattah AM et al Pharm Res. 24 (4): Human serum albumin: Hajare AA et al Curr Drug Deliv. Francisella tularensis live vaccine: Ohtake S et al J Pharm Sci. 8 (6): Salmonella typhi live vaccine: Ohtake S et al Vaccine. 29 (15): LaSota virus: Pisal S et al AAPS PharmSciTech. 7 (3): 60.
8 Benefits of PBV Technology: Higher activity titer after drying and thermostability during subsequent storage (increased shelf-life). Eliminates the need of using a cold chain. Allows subsequent particle size reduction (micronization). Allows drying of vaccines encapsulated in gel microparticles for better intestinal delivery avoiding the need of reconstitution with water. Allows short-term (several hours) stability at 60 C to 90 C that could be used for encapsulation of dry powders in dissolvable polymeric films for buccal and transdermal delivery avoiding a need of reconstitution with water. Allows scalable continuous load barrier drying. Eliminate drawbacks of PFF.
9 Formulation of Patches and Quick-Dissolve Films for Delivery of Biopharmaceuticals 1. To make patches for transdermal delivery and quick-dissolve films for buccal, sublingual, and vaginal delivery, we cast liquid mixtures comprising water-soluble polymer, plasticizer, and sugar glass particles with biopharmaceuticals preserved inside the sugar glass into a mold. 2. The liquid mixtures can be prepared by melting polymer at elevated temperatures or by dissolving polymers in anhydrous solvents that do not dissolve the sugar glass. Sugar glass particles should be phase separated from the polymer in both solid and liquid state before casting. In addition, incorporating sugar glass particles inside a water-soluble polymer matrix should be performed in low humidity environment to avoid decrease of the sugar glass transition temperature. 3. Casting can be achieved by solidifying the melted polymers or polymer solutions in a mold by cooling, by evaporation of the solvent, fusion of polymeric powders by application of mechanical stresses, or by polymerizing monomers using irradiation or application of other physical and chemical factors. 4. To ensure that biopharmaceuticals can be placed inside melted polymer matrixes, we make preserved biopharmaceuticals thermostable for the short-term (i.e. an hour at 70 C to 90 C). For casting processes that include solvent evaporation we select solvents that are phase separated from sugar glass and do not harm biopharmaceuticals preserved inside the glass.
10 Quick-Dissolve Film Produced by Solvent Casting Method (In Collaboration with Dr. Lisa Rohan s Lab at MWRI) Magee Womens Research Institute
11 Examples of PBV Formulations for Proteins:
12 hbche Activity (%) Stability of Thermostabilized Butyrylcholiesterase (hbche) at High Temperatures C 37 C Room Temperature Time of Storage (month)
13 PA83 PBV Formulations: Immunogenicity
14 Immunogenicity of PA83 Foam-Dried Formulations P4 and P5 Experimental Design: Primary Immunization Secondary immunization Bleed 3 weeks 3 weeks Pre-bleed Day 21 Day 42 Day 70 Groups Balb/c 6wks Vaccine candidate Formulation Form Route Alhydrogel Dose at days 0 and 21 (µg/dose) 1 6 PA83 P4A Foam IM 0.3% PA83 P4B Foam IM 0.3% PA83 P5A Foam IM 0.3% PA83 P5B Foam IM 0.3% Saline Saline N/A IM 0.3% 7.5
15 Anthrax Lethal Toxin Neutralizing Antibody (TNA) Titers 7.5 (5) µg 0.3% Alhydrogel Formulation 4A 4B 5A 5B PA83 Saline Saline only GMT ED 50 ± SE Day 20 15±3 13±1 17±4 20±4 21±3 19±2 Day ± ± ± ± ± ± 0 Day ± ± ± ± ± ± 1 % Responders Day 42 67% 50% 100% 50% 50% 0% % Responders Day 70 67% 50% 100% 67% 67% 0% Data are represented at geometric mean effective dose 50 (ED 50 ) titers (GMT) % responders are determined when the GMT of a samples is to the GMT of a PA mab Results show that formulation P5A generated the highest TNA titers with 100% of mice responding after the booster dose. The response decreased slightly by study day 70, but remained significantly higher than the rest of the groups. The other foam dried formulations behaved similarly to the PA83 is saline.
16 PA83 Foam Dried Formulations: Stability at 37ºC
17 Foam dried Formulations Stability at 37 C: SDS PAGE and Western Blot Data
18 Summary and Conclusions SDS PAGE and Western blot data suggest that foam dried PA83 5A formulation is stable for 6 months at 37 C. Reconstituted PA83 after 6 month storage at 37 C does not lose its potential to bind to Alhydrogel adjuvant, as determined by the absence of the target molecule from the supernatant after Alhydrogel removal by centrifugation.
19 Examples of PBV Formulations for Viral Vaccines:
20 Thermostability and Activity of Live ERA Rabies Vaccine after PBV Drying and Encapsulation in Polyethylene Glycol (PEG) MW 35, Rabies vaccine activity titer (log FFU/ml) Activity be fore drying Activity afte r drying Activity after 3 hours at 80 C Activity after encapsulation in PEG at 80 C Activity Activity ater 23 ater months 23 m at onths RT at RT Activity after 1 m onth at 37 C 0
21 Stability of PBV Preserved YF-VAX Vaccine17D at 37 C. Activity of YF-17D vaccine (log 10 PFU/0.5ml) Form. that do not contain MAG (Metyl Glycoside) Control stored Control at -80 C Stored at -80 C Form. containing MAG Activity of Freeze-Dried YF-VAX 17D Activity Manufactured of freeze-dried by Sanofi YF-VAX Pasteur, 17D vaccine Inc. manufactured by Sanofi Pasteur Inc. Titer After 15 Months at RT: 4.55±0.23 (log 10 PFU/0.5ml) Formulations Including MAG Days of storage at 37 C Formulations Not Including MAG
22 Particle Size Distribution After Jet Milling of PBV Preserved YF-VAX 17D 14 Statistics Graph (65 measurements) 10µm Volume (%) Mean with +/- 1 Standard deviation error bar Particle Size (µm)
23 Stability of PBV Preserved MVA at 37 C 8 Activity Titer (Log 10 PFU/ml) 7 6 Formulation 1 Formulation 2 (Includes MAG) Formulation 3 (Includes MAG) Formulation 4 Stability of freeze-dried MVA vaccine (Baxter) Time of Storage at 37 C (Weeks)
24 PBV Preserved YF-VAX 17D Can be Micronized Using Jet Milling with Minimum Activity Loss 7 6 Titer (log 10 PFU/0.5ml) Titer of Preservation Mixture Before Drying Titer After Drying Titer Aftert Jet Milling (Micronization) 0
25 Stability of PBV Preserved Measles Vaccine at 37 C (Evaluated in Dr. Rota s Laboratory at CDC) % of Vaccine Activity Before Drying Measured in TCID50/ml Time of storage at 37 C (Months)
26 Examples of PBV Formulations for Bacteria:
27 Survival of PBV bacteria (10 8 CFU/ml) at 37 C and 70 C Treatment Activity of L. rhamnosus Activity of L. jensenii Activity of L. crispatus Before drying Form. 1 Form. 2 Form ± ±15 118±12 137±12 119±14 95±28 94±9 93±14 After drying Form. 1 Form. 2 Form. 3 After 1 hour at 70ºC Form. 1 Form. 2 Form. 3 After 3 months at 37ºC Form. 1 Form. 2 Form. 3 After 6 months at 37ºC Form. 1 Form. 2 Form. 3 After 11 months at 37ºC Form. 1 Form. 2 Form. 3 After 11 months at RT Form. 1 Form. 2 Form. 3 93±1.5 77±8 103±14 81±6 56±21 109±3 78±6 69±3 15±6 49±7 31±8 3.4±0.6 76±7 2.4±1.7 1± ±10 100±16 68±6 110±15 106±12 126±22 101±8 85±11 104±19 116±20 49±29 54±9 31±7 47±3 23±4 42±3 31±3 4.5±1 86±15 86±10 94±16 70±12 65±13 67±8 67±8 50±3 56±9 52±9 37±6 53±15 52±12 25±3 40±7 33± ±19 36±11 2.5±2.5
28 L. Rhamnosus PBV Formulation Micronized Using Jet Milling 200 μm 100 μm
29 Quick-Dissolve Film Produced by Solvent Casting Method (In Collaboration with Dr. Lisa Rohan s Lab at MWRI) Magee Womens Research Institute
30 Acknowledgements We would like to thank our collaborators from CDC and University of Pittsburg who allowed to share with you some results of our work.
At LATITUDE, we only do one thing, and we do it very well.
Formulation Experts for Insoluble Compounds At LATITUDE, we only do one thing, and we do it very well. LATITUDE Pharmaceuticals Inc. has been tackling the most difficult drug formulation challenges for
More informationEVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS
EVALUATION OF NEW FILM COATING PROCESSES AND MATERIALS Inaugural-Dissertation zur Erlangung der Doktorwurde im Fachbereich Biologie, Chemie, Pharmazie der Freien Universitat Berlin vorgelegt von NANTHARAT
More informationDevelopment of Vaxfectin -formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications
Development of Vaxfectin -formulated HSV-2 Plasmid DNA Vaccines for Prophylactic and Therapeutic Applications Sean M. Sullivan, Ph.D. Executive Director Pharmaceutical Sciences 14 July 2011 - DNA Vaccines
More informationFoam Drying and Foam Freeze Drying Process Loss and Stability
Foam Drying and Foam Freeze Drying Process Loss and Stability Reinhard Vehring Associate Director, Solid Dosage Forms MedImmune Inc. 319 North Bernardo Ave, Mountain View, CA 94043 Outline Introduction
More informationHigh-Concentration Monoclonal Antibody Powder Suspension in Non-aqueous Vehicle for Subcutaneous Injection
Slide 1 High-Concentration Monoclonal Antibody Powder Suspension in Non-aqueous Vehicle for Subcutaneous Injection Mayumi Bowen Pharmaceutical Processing & Technology Development Genentech, Inc AAPS Annual
More informationBalancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL
Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels
More informationHowida Kamal, Ph.D. Ass. Prof. of Pharmaceutics, Cairo University
Howida Kamal, Ph.D Ass. Prof. of Pharmaceutics, Cairo University Dosage forms Sterile Free from all forms of microbial life (vegetative & sporing) Free from pathogens Non-sterile Extent of total bioburden
More informationInstitute of Pharmaceutical Technololgy and Biopharmacy University of Pécs
Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs 1 Faculty of Pharmacy H-7624 Pécs, Rókus str.2. 2 Faculty of Pharmacy Department of Pharmacetical Biotechnology Department of
More informationPerformance Testing of Novel Dosage Forms
RQA Ireland Regional Forum - Athlone, May 2016 Quality Considerations Pharma and Biopharma Performance Testing of Novel Dosage Forms Terry Way BPharm MAPS Dissolution Science Consultant Glasside Technologies
More informationYoung Innovators 2011
Young Innovators 2011 Formulation of Novel Particulate Breast Cancer Vaccines using Spray Drying and In Vivo Evaluation of Vaccine Efficacy 2011 AAPS Graduate Student Symposium Awards in Biotechnology
More informationIssues Related to the Formulation and Delivery of Pharmaceutical Proteins
Issues Related to the Formulation and Delivery of Pharmaceutical Proteins Pretoria16 August Prof. dr. Daan J.A. Crommelin Dept. Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, UIPS Scientific
More informationThe science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form.
The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. Three major needs that the formulation into a specific dosage form directly address
More information6. In this temperature time graph for the heating of H 2O at a constant rate, the segment DE represents the
1. Which of the following contains particles with the least freedom of motion? A) CO 2( ) B) HCl(aq) C) F 2(g) D) MgBr 2(s) E) C 6H 12O 6(aq) 2. During boiling, the temperature of a pure liquid substance
More informationDRY COATING : Techniques & Potentials
Water in Food Workshop Lausanne 2004 DRY COATING : Techniques & Potentials E. TEUNOU - E. IVANOVA - D. PONCELET Nantes Département du Génie des Procédés Alimentaire Content Who are we? Importance and Functionality
More informationIIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES
IIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES IIS REVOLUTIONARY ADMINISTRATION TECHNIQUES MORE EFFICIENCY AND SAFETY IIS researches and develops innovative injection systems. Within
More informationRecombinant, Insect Cell-Derived RSV Nanoparticle Vaccine
Recombinant, Insect Cell-Derived RSV Nanoparticle Vaccine Gregory Glenn Chief Medical Officer MVADS-Copenhagen 4 July 2012 1 Agenda for RSV Discussion Overview of Insect Cell Technology Respiratory Syncytial
More informationDESIGN AND ENGINEERING OF INJECTABLE MICROPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC PROTEINS USING A SUPERCRITICAL FLUID COATING PROCESS
DESIGN AND ENGINEERING OF INJECTABLE MICROPARTICLES FOR SUSTAINED RELEASE OF THERAPEUTIC PROTEINS USING A SUPERCRITICAL FLUID COATING PROCESS F.S. Deschamps 1, A.M. DeConti 2, O. Thomas 1, R. Aubreton
More informationGuidelines for Pharmaceutical Equivalence Requirements
Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority
More informationFOOD AND DRUGS AUTHORITY
G H A N A FOOD AND DRUGS AUTHORITY GUIDELINES FOR STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS AND FINISHED PHARMACEUTICAL PRODUCTS Document No: FDA/DRI/DER/GL-STP/2013/07 Date of First Adoption:
More informationLichenase fusions improve immunological properties of antigens
Lichenase fusions improve immunological properties of antigens Konstantin Musiychuk Center for Molecular Biotechnology, Fraunhofer USA 03/27/2012 Lichenase Hydrolysis site of β-glycans Structure of the
More informationBioConvergence Technical Paper
BioConvergence Technical Paper # 2012001 Application of Thermal Analysis in Lyophilization Development and Optimization Kara Strass* and Kelly L. Zaleski, Ph.D.* *BioConvergence LLC, 4320 West Zenith Drive,
More informationFormulation Development & CTM Manufacturing Services
Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range
More informationFlock House virus VLPs as a tool in structure-based vaccine design. Malaria VLP Development Workshop September 23, 2009
Flock House virus VLPs as a tool in structure-based vaccine design Malaria VLP Development Workshop September 23, 2009 Flock House virus X-ray structure solved at 2.8 Å resolution Particle diameter 35
More informationSoluplus. Technical Information. October _090801e-01/Page 1 of 8. = Registered trademark of BASF group. Pharma Ingredients & Services
Technical Information Soluplus October 2009 03_090801e-01/Page 1 of 8 = Registered trademark of BASF group Pharma Ingredients & Services 03_090801e-01 October 2009 Page 2 of 8 Soluplus 1. Introduction
More informationSupercritical Fluid (SCF) Drying of Pharmaceuticals Peter York Chief Scientist, CrystecPharma
Supercritical Fluid (SCF) Drying of Pharmaceuticals Peter York Chief Scientist, CrystecPharma APS Focus Group Meeting, Loughborough 28 th January 2015 Presentation overview Introduction to SCF technologies
More informationResearch Article Pharmaceutical Sciences
Page185 Research Article Pharmaceutical Sciences ENHANCEMENT OF DISSOLUTION RATE OF EFAVIRENZ BY SOLID DISPERSION TECHNIQUE B. Venkateswara Reddy 1*, K.V. Ramana Murthy 2 1* Department of Pharmaceutics,
More informationExtractables & Leachables. Ophthalmic Drug Products: A Regulatory Perspective Current Industry Challenges and Case Studies
Extractables & Leachables Ophthalmic Drug Products: A Regulatory Perspective Current Industry Challenges and Case Studies Ph.D. Pfizer Global Research and Development Bethesda 23/02/2011 Thresholds and
More informationWe Care for Proteins Stabilization and Protection of Biopharmaceuticals, Vaccines and Biologic-Device Combination Products
We Care for Proteins Stabilization and Protection of Biopharmaceuticals, Vaccines and Biologic-Device Combination Products Munich, June 2013 LEUKOCARE AG Established 2003 Owner Management and Private Investors
More informationCustom Antibodies Services. GeneCust Europe. GeneCust Europe
GeneCust Europe Laboratoire de Biotechnologie du Luxembourg S.A. 2 route de Remich L-5690 Ellange Luxembourg Tél. : +352 27620411 Fax : +352 27620412 Email : info@genecust.com Web : www.genecust.com Custom
More informationSpray-drying Biotherapeutics
Spray-drying Biotherapeutics Richard Kaye Investigator Product Development GSK R&D APS Freeze Drying and Alternative Drying Technologies for Parenterals Burleigh Court, Loughborough 28th January 2015 Contents
More informationSUSTAINED RELEASE From Coated Ion Exchange Resins. H.S. Hall Coating Place, Inc. Verona, WI 53593
SUSTAINED RELEASE From Coated Ion Exchange Resins 79-1 by H.S. Hall Coating Place, Inc. Verona, WI 53593 A substantial amount of work has been published concerning the use of ion exchange resins for sustained
More informationExperimental design on product development
Experimental design on product development Introduction What is the traditional developing method? What is experimental design? What do we need and what kind of possibilities do we have for designing?
More informationApplications of self-assembling peptides in controlled drug delivery
Applications of self-assembling peptides in controlled drug delivery Sotirios Koutsopoulos, Ph.D. Problems associated with drug administration Drug concentration in blood C toxic C effective Time 1 The
More informationPharmaceutical Sciences
SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning
More informationCONSIDERATIONS FOR DEVELOPMENT OF A LYOPHILIZED BIOSIMILAR
CONSIDERATIONS FOR DEVELOPMENT OF A LYOPHILIZED BIOSIMILAR A Case Study The patents for a number of parental biologic formulations are destined to expire in the United States between 2016 and 2027. Some
More informationImmunofluorescence and phalloidin labeling of mammalian cells
Immunofluorescence and phalloidin labeling of mammalian cells 2 Contents Materials for immunofluorescence and phalloidin labeling of mammalian cells...1 Immunofluorescence-labelling on cultivated adherent
More informationEvaluation of Clindamycin encapsulated in PLA/PLGA nanoparticles
Evaluation of Clindamycin encapsulated in PLA/PLGA nanoparticles Presented by Dr. Bismita Nayak bismita.nayak@gmail.com, nayakb@nitrkl.ac.in Department of Life science National Institute of Technology
More informationPharma Ingredients & Services. Kollicoat IR White. Technical Information
Technical Information Kollicoat IR White August 2008 Supersedes issue dated June 2008 EMP 040901e-10/Page 1 of 12 = Registered trademark of BASF SE Ready-to-use coating for instant-release dosage forms
More informationOrodispersible drug delivery systems
Orodispersible drug delivery systems Orodispersible drug delivery systems Disintegrate and/or dissolve rapidly in the saliva without the need for water. Tablets Films Fast-dissolving tablets are designed
More informationHigher Order mab Aggregate Analysis using New Innovative SEC Technology
Higher Order mab Aggregate Analysis using New Innovative SEC Technology Ronald E. Majors, Ph.D. LCGC No. America West Chester, PA USA WCBP 2016 Washington, DC Linda Lloyd, Ph.D. Agilent Technologies Church
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationSupplementary Figure 1.
Supplementary Figure 1. Assessment of quaternary structure of soluble RSV F proteins. Soluble variants of F proteins from A2 and B1 RSV strains were expressed in HEK293 cells. The cell culture supernatants
More informationInjection Moulding as a One-Stop-Production to Produce Pharmaceutical Dosage Forms
Injection Moulding as a One-Stop-Production to Produce Pharmaceutical Dosage Forms Karin Eggenreich, Simone Schrank, Gerold Koscher, Daniel Treffer, Eva Roblegg and Johannes G. Khinast K1 Competence Center
More informationComputation of Solubility parameters using Molecular. dynamics simulation
Appendix I Appendix I Computation of Solubility parameters using Molecular dynamics simulation Computational Methods Molecular dynamics (MD) simulations were carried out using the Accelrys Materials Studio[1]
More informationPharmaceutical Development for ADCs: Not as Simple as ABC
Pharmaceutical Development for ADCs: Not as Simple as ABC Pharmaceutical Development for ADCs Formulation, process, and analytical development for antibody-drug conjugates, or ADCs, is complex. While the
More informationMETHODS IN CELL BIOLOGY EXAM II, MARCH 26, 2008
NAME KEY METHODS IN CELL BIOLOGY EXAM II, MARCH 26, 2008 1. DEFINITIONS (30 points). Briefly (1-3 sentences, phrases, word, etc.) define the following terms or answer question. A. depot effect refers to
More informationThe 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice
The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability WHO Biowaiver Guideline in Regulatory Practice Dr Kamel IDDIR General Director Medicines and Pharmacy Directorate Berne
More informationGENERAL PHARMACOPOEIA MONOGRAPH
MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION GENERAL PHARMACOPOEIA MONOGRAPH Immunobiological GPM. 1.8.1.0002.15 medicinal products First Edition The present General Pharmacopoeia Monograph applies to
More informationnanoprecipitation mpeg-pla 2 nd Emulsion mpeg-pla in DCM
THERAPEUTIC NANOTECHNOLOGY LAB MODULE Location: BioNano Lab, 3119 Micro and Nanotechnology Laboratory (MNTL) Instructor: Jianjun Cheng, Assistant Professor of Materials Science and Engineering Lab Assistants:
More informationWe make drugs smarter
We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities
More informationThe Role of Compounded Medicines in Therapy. Loyd V. Allen, Jr., Ph.D.,R.Ph. Editor-in International Journal of Pharmaceutical Compounding
The Role of Compounded Medicines in Therapy Loyd V. Allen, Jr., Ph.D.,R.Ph. Editor-in in-chief International Journal of Pharmaceutical Compounding Contact Information www.ijpc.com Lallen@ijpc.com 122 N.
More informationMag4C-Lv Kit - Results
Mag4C-Lv Kit - Results Mag4C-Lv Kit Magnetic capture for viral concentration & storage buffer for superior viral preservation OZ Biosciences is delighted to announce the launching of a new product Mag4C-Lv
More informationFreeze Granulation for Processing of Nano Materials. Kent Rundgren, President of PowderPro AB
Freeze Granulation for Processing of Nano Materials Kent Rundgren, President of PowderPro AB Freeze Granulation Process Suspension Spray freezing Air Freeze drying Vacuum Atomisation Sublimation Instant
More informationHIGH PRESSURE MICRONISATION OF POLYMERS
HIGH PRESSURE MICRONISATION OF POLYMERS Željko Knez University of Maribor, Faculty of Chemistry and Chemical Engineering, Smetanova 17, SI-2000 Maribor, Slovenia Fax: +386 2 25 16 750, e-mail: zeljko.knez@uni-mb.si
More informationBean common mosaic virus (BCMV) ELISA Kit
Bean common mosaic virus (BCMV) ELISA Kit Cat.No: DEIAPV17 Lot. No. (See product label) Size 5000T Intended use The test can be used to detect BCMV in infected host plants. General Description Bean common
More informationEvonik Birmingham Laboratories
Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories
More informationDr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur
Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended
More informationHandbook Controlled Release Of Drugs Polymers And Aggregate Systems
Handbook Controlled Release Of Drugs Polymers And Aggregate Systems (1) The development of controlled release drug delivery system has long been a major area of bipinnata, which is used as release retardant
More informationUsing the Sartobind pico
Using the Sartobind pico Optimizing Steps for using micro-scale membrane adsorbers on liquid chromatography systems Application Note Steps for the successful use of Sartobind pico 1. Start with a new unused
More informationAnti-Tilapia (Oreochromis niloticus) IgM monoclonal antibody. Product no: F04
Anti-Tilapia (Oreochromis niloticus) IgM monoclonal antibody Product no: F04 Product Description This monoclonal antibody (Mab) reacts with Anti-Tilapia (Oreochromis niloticus) immunoglobulin M (IgM).
More informationINTRODUCTION TO INDUSTRIAL PHARMACY LAB 1
INTRODUCTION TO INDUSTRIAL PHARMACY LAB 1 LAB INSTRUCTORS: LECT. ANAS T ARIK NAFEA ASSIST. LECT. ZAINAB HASSAN MAHDI Definition of Industrial Pharmacy The conversion of raw materials into certain dosage
More informationPQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products
PQRI Research Project Proposal: Reporting and Qualification Thresholds for Leachables in Parenteral and Ophthalmic Drug Products Prepared by: Doug Ball (Pfizer), Diane Paskiet (West-Monarch), Daniel L.
More informationPhysical pharmacy. dr basam al zayady
Physical pharmacy Lec 5 dr basam al zayady Liquefaction of Gases: When a gas is cooled, it loses some of its kinetic energy in the form of heat, and the velocity of the molecules decreases. If pressure
More informationChapter 9 Controlling Microbial Growth in the Environment. 10/1/ MDufilho
Chapter 9 Controlling Microbial Growth in the Environment 10/1/2017 1 MDufilho Table 91 Terminology of Microbial Control 10/1/2017 MDufilho 2 Number of living microbes Figure 91 A plot of microbial death
More informationSera-Mag SpeedBeads Magnetic Protein A/G Particles
Procedure 29-1079-14 AA Protein enrichment Sera-Mag SpeedBeads Magnetic Protein A/G Particles Sera-Mag SpeedBeads Protein A/G Magnetic Particles (Table 1) provide a fast and convenient method for both
More informationInternational Journal of Pharma and Bio Sciences
S. HONARY 1, P. EBRAHIMI 2 AND N. EMRANI 1 1 Mazandaran University of Medical Sciences, School of Pharmacy, Phrmaceutical Research Center, Sari, Iran 2 Gonbad Institute of Higher Education, P. O. Box 163,
More informationProtein A Agarose Immunoprecipitation Kit
Protein A Agarose Immunoprecipitation Kit Catalog Number KA0568 20 Reactions Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information...
More informationEZ-10 SPIN COLUMN GENOMIC DNA MINIPREPS KIT HANDBOOK
EZ-0 SPIN COLUMN GENOMIC DNA MINIPREPS KIT HANDBOOK (Bacteria, Plant, Animal, Blood) Version 8 Rev 05/0/03 EZ-0 Genomic DNA Kit Handbook Table of Contents Introduction Limitations of Use Features Applications
More informationCONTRACTING ORGANIZATION: Albert Einstein College of Medicine Bronx, NY 10461
AD Award Number: W81XWH-08-1-0011 TITLE: Defining B. Anthracis Protective Antigen Antigenic Domains PRINCIPAL INVESTIGATOR: Arturo Casadevall, M.D., Ph.D. CONTRACTING ORGANIZATION: Albert Einstein College
More informationMETHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow
METHOCEL Cellulose Ethers A product that can do it all TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow The possibilities are endless Pharmaceutical companies are continuously
More informationAnswer ALL questions. Use the answer grid provided for ALL of your answers. For each of the following questions there is ONE correct answer only.
UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-14 SPECIAL PAPER FOR: PHARMACEUTICAL TECHNOLOGY PHA-2FGY Time allowed: 2 hours Part ONE Answer ALL questions. Use the answer
More informationDynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors
Contact Us: www.pall.com/contact Dynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors Dynamic High Capacity Mustang Q Membrane Units
More informationDesign and Dosage Form. Dr. Deny Susanti
Design and Dosage Form Dr. Deny Susanti Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note:
More informationRapidChek SELECT Salmonella Enteritidis Test System
RapidChek SELECT Salmonella Enteritidis Test System Part #: 7000220, 7000221, 7000222, 7000228 AOAC Approved Protocols: This test kit s performance was reviewed by AOAC Research Institute and was found
More informationPolymorph Screening Strategies and a Concomitant Polymorph Case Study
Polymorph Screening Strategies and a Concomitant Polymorph Case Study Aniruddh Andy Singh, Ph.D. Mahmoud Mirmehrabi, Ph.D., P.Eng. Johnson Matthey Pharma Services Chemical and Crystallization Research
More informationLeading Pharmaceutical Innovation
Leading Pharmaceutical Innovation Hyaluronic Acid Experts Leading Pharmaceutical Innovation Altergon, born in 2000 in Morra de Sanctis (Avellino) represents a Centre of Excellence and Innovation for the
More informationCat. No. MG17PG-1ml XPRESSAFFINITY PROTEIN G- MAGNETIC NANOPARTICLES (MNP) FOR RESEARCH APPLICATIONS
Cat. No. MG17PG-1ml XPRESSAFFINITY PROTEIN G- MAGNETIC NANOPARTICLES (MNP) FOR RESEARCH APPLICATIONS Product Description: MagGenome s Protein G-MNP provides a fast and convenient method for affinity based
More informationTransdermal Drug Delivery System Regulatory Requirements (USA)
Transdermal Drug Delivery System Regulatory Requirements (USA) Vinod P. Shah, Ph. D., FIP Scientific Secretary Conference on To and Thru the Skin IPA AAPS FIP - APSTJ Mumbai, India, February 20-21, 2009
More informationProduct Permission Document (PPD) of Typhoid Polysaccharide Vaccine I.P. (Brand Name Bio-Typh TM )
1 Product Permission Document (PPD) of Typhoid Polysaccharide Vaccine I.P. (Brand Name Bio-Typh TM ) 1. Introduction Typhoid Polysaccharide Vaccine is a preparation of purified Vi capsular polysaccharide
More informationScalable Strategies for Parenteral Dosage Form Selection
Scalable Strategies for Parenteral Dosage Form Selection Tony Pidgeon Process Technology Director Pharma Services Patheon, part of Thermo Fisher Scientific There are many parenteral dosage forms from which
More information: Scientific research and development,use as laboratory reagent,manufacture of substances
SECTION 1: Identification 1.1. Identification Product form Poly(ethylene glycol), MW 400 (PEG 400) Date of issue: 11/21/2017 Revision date: 11/21/2017 Supersedes: 11/15/2013 Version: 2.0 : Substance Substance
More informationGenomic DNA Mini Kit (Blood/Cultured Cell) For research use only
Genomic DNA Mini Kit (Blood/Cultured Cell) For research use only Sample : up to 300 µl of whole blood, up to 200 µl of frozen blood, up to 200 µl of buffy coat, cultured animal cells (up to 1 x 107), 9
More informationHELENA LABORATORIES 1530 Lindbergh Dr. / P.O. Box 752 Beaumont, TX USA Toll Free
SDS: 3040 Page 1 of 8 SAFETY DATA SHEET HELENA LABORATORIES 1530 Lindbergh Dr. / P.O. Box 752 Beaumont, TX 77704 0752 USA Toll Free 800 231 5663 DATE PREPARED: 6/7/2017 REVISION: 2 1. IDENTIFICATION Product
More informationPD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair
PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair Pack Size: 96 tests / 480 tests Catalog Number:EP-101 IMPORTANT: Please carefully read this manual before performing your experiment. For
More informationMaterial Safety Data Sheet
Material Safety Data Sheet 28 Jan 2012 Version 1.0 Material Safety Data Sheet Human Serum Albumin (HSA 10% Solution). Section 1 - Product and Company Identification 1.1 Product Name: Human Serum Albumin
More informationWhite Paper. Advancing the Understanding of Emulsions in Food Products Using State of the Art Microscopy. Haixia Xu Scientist, Microscopy
White Paper Advancing the Understanding of Emulsions in Food Products Using Haixia Xu Scientist, Microscopy Introduction The importance of understanding food microstructure should not be underestimated.
More informationSoil DNA Extraction Kit
Instruction Manual Ver. 09.23.16 For Research Use Only Soil DNA Extraction Kit Advantages IB47800 (4 Preparation Sample Kit) IB47801 (50 Preparation Kit) IB47802 (100 Preparation Kit) Sample: 250-500 mg
More informationPresto 96 Well gdna Bacteria Kit
Presto 96 Well gdna Bacteria Kit 96GBB02 (2 x 96 well plates/kit) 96GBB04 (4 x 96 well plates/kit) 96GBB10 (10 x 96 well plates/kit) Instruction Manual Ver. 05.04.17 For Research Use Only Advantages Sample:
More informationMucosal Immunity induced by VLPs
Virus-like paticles (VLPs) as vaccines, vectors and adjuvants, Fondation Mérieux, Annecy, 04 Mucosal Immunity induced by VLPs Denise Nardelli-Haefliger Lausanne University Hospital, Switzerland Purified
More informationRegulatory Challenges for the Licensure of Future Vaccines
Regulatory Challenges for the Licensure of Future Vaccines Tong Wu, Ph.D. Bacterial & Combination Vaccine Division, BGTD, Health Canada June 26-29, 2018, Seoul, Korea, the Global Bio Conference 1 Disclaimer
More informationVaccine Cuisine EDIBLE VACCINES. Nina Gloriani Barzaga, M.D.,Ph.D. University of the Philippines Manila
Slide 1 Plant Made Pharmaceuticals EDIBLE VACCINES Vaccine Cuisine Nina Gloriani Barzaga, M.D.,Ph.D. University of the Philippines Manila 3 rd Asian Biotechnology Conference, Manila Nov 9-10, 2006 Slide
More informationAlternatives to In-Vivo Testing for Animal Biologics: North American Regulatory Perspective
Alternatives to In-Vivo Testing for Animal Biologics: North American Regulatory Perspective Geetha B. Srinivas, DVM, PhD Section Leader, Virology Center for Veterinary Biologics USDA/APHIS/VS IABS 2018,
More informationA Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile
A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Clostridium difficile vaccine administered with or without Aluminum Hydroxide, in a 3-Dose Regimen in Healthy Adults Aged 50
More informationApproaches to the formulation of poorly soluble drugs
1 Approaches to the formulation of poorly soluble drugs R. Christian Moreton, Ph.D FinnBrit Consulting ExcipientFest 2013, April 30 May 01, 2013, Baltimore, MD 2 Disclaimer The views expressed in this
More informationOPTIMIZATION OF FORMULATION OF FAST DISSOLVING FILMS MADE OF PULLULAN POLYMER
Research Article OPTIMIZATION OF FORMULATION OF FAST DISSOLVING FILMS MADE OF PULLULAN POLYMER Accepted on: 04-04-2011; Finalized on: 06-07-2011. ABSTRACT Seema Saini 1, Samta 1*, A. C. Rana 1, and Sumit
More informationVWR CO 2 RESISTANT TUBES
VWR CO 2 RESISTANT TUBES Protects Samples Shipped on Keeps ph Stable CO 2 Resistant Certified for Shipping VWR CO 2 VWR CO 2 Only VWR s CO 2 Resistant Tubes are designed to protect samples that are shipped
More informationHigh-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns
High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns Agilent AdvanceBio SEC 3 Å, 2.7 µm columns Application note Bio-Pharmaceutical Author
More informationI Jornada: Oportunidades de negocio en nanotecnología
I Jornada: Oportunidades de negocio en nanotecnología NanoBioTer Maximizing polymer potential through flexible nanotechnology Contents About Us Technology Selected Data Production process and Products
More informationDNA isolation from tissue DNA isolation from eukaryotic cells (max. 5 x 106 cells) DNA isolation from paraffin embedded tissue
INDEX KIT COMPONENTS 3 STORAGE AND STABILITY 3 BINDING CAPACITY 3 INTRODUCTION 3 IMPORTANT NOTES 4 EUROGOLD TISSUE DNA MINI KIT PROTOCOLS 5 A. DNA isolation from tissue 5 B. DNA isolation from eukaryotic
More information